Questions? Feedback? powered by Olark live chat software
All Site

Premier Cell Analysis Instrument” Award for 2016 - ACEA Biosciences xCELLigence Instruments

ACEA’s line of real-time cell analyzers has been awarded top honors from Corporate Vision Magazine - for their ability to quantitatively monitor, in a label-free manner, cell number, morphology, and adhesion strength for a broad array of applications.

The ACEA Biosciences xCELLigence Real-Time Cell Analyzers enable to monitor in a non-invasive manner cell health and behavior. This technology can be implemented in wide variety of assays, from immune cell-mediated killing of cancer cells to cancer cell invasion/migration, and cardiotoxicity to nuclear hormone receptor signaling.

Dr. Xiaobo Wang, ACEA’s Chief Technology Officer gave an interview for CV Magazine, where he explained that from its foundation a major goal of ACEA has been to “transform cell-based assays by improving the accuracy, reliability, and scope of cell measurements,” so that dynamic responses to small molecules, biomolecules, or other cells in culture can be evaluated. Nowadays 1800 xCELLigence instruments are in use globally, resulting in over 1250 publications in various research fields. Please click here to see complete interview with Dr. Wang.

ACEA Biosciences

Founded in 2002, ACEA Biosciences is a pioneer in the development and commercialization of high performance, cutting edge cell analysis platforms for life science research. ACEA’s xCELLigence®
impedance-based, label-free, real-time cell analysis instruments and NovoCyte® flow cytometer are used in pre-clinical drug discovery and development, toxicology, safety pharmacology, and basic academic research. More than 2,000 instruments have been placed globally, leading to >1,200 peer reviewed publications. Please click here for more information.